drugset / Trial / NCT00251550

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

NCT00251550

Phase 1/2 Completed 12 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.

Timeline

Start
2005-10
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified
Subject Pemetrexed Small molecule